ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Br J Cancer · 2026-07-18

In 31 patients with platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma progressing on nivolumab, adding ipilimumab gave 0% response vs 17.6% with docetaxel; median PFS was shorter (1.97 vs 3.66 months), but grade ≥3 events fewer (38.5% vs 68.8%).

RCTn = 31
Grünwald et al. OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)
Oncology · Lancet Oncol · 2026-07-08

Phase 3 trial, 102 adults with gastric cancer and limited peritoneal metastases: gastrectomy, cytoreductive surgery and HIPEC did not improve survival vs systemic therapy alone (median OS 15·7 vs 16·6 months; HR 1·10, p=0·70); serious adverse events 44% vs 6%.

RCTn = 102
Quik et al. Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis
Oncology · ESMO Open · 2025-11-27

In 10-year registry follow-up of 699 PlanB trial patients with HR-positive, HER2-negative early breast cancer, invasive disease-free survival was similar with six cycles of TC and with EC-T (90.8% vs 92.1%, P = 0.546); overall survival was 96.8% vs 96.3%.

RCTn = 699
Nitz et al. Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.